83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
Watch Crinetics Pharmaceuticals' latest callCrinetics Pharmaceuticals (NASDAQ:CRNX) Q1 2026 Earnings Call · Replay · May 7Read the transcript of Crinetics Pharmaceuticals (NASDAQ:CRNX) Q1 2026 Earnings CallCrinetics Pharmaceuticals, Inc. on 6ix
In the deck
Story so far
- Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
- Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
- Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress
Earlier from Crinetics Pharmaceuticals
- Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
- New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
- Crinetics to Highlight Broad Pipeline at ENDO 2023
- Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Later from Crinetics Pharmaceuticals
- Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
- Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
Follow Crinetics Pharmaceuticals into a list and get an email when it puts out news.
Follow Crinetics Pharmaceuticals